Clinical Trials Browser

Not yet recruiting × osimertinib × Thoracic × Clear all

NCT07486648 2026-03-24

Precision

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07485452 2026-03-20

OSIBBBOOST

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07376382 2026-02-02

SYNSTAR-02

Phase 3 Not yet recruiting

NSCLC

NCT07329322 2026-01-09

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07323641 2026-01-07

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07153055 2025-12-18

LOTS

Phase 1/2 Not yet recruiting

Small Cell Lung Carcinoma

NCT07285148 2025-12-16

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07256509 2025-12-05

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07177092 2025-09-16

SURGAN-TKI

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07038460 2025-06-26

NEO-LISI

Phase 2 Not yet recruiting

Resectable Non-small Cell Lung Cancer

NCT06918782 2025-04-09

Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06752408 2024-12-30

ANOTHER

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06709274 2024-11-29

MOTION-NSCLC

Phase NA Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06557096 2024-08-16

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

Phase EARLY_PHASE1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Neoplastic Cells, Circulating

NCT06530719 2024-07-31

A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06452433 2024-06-11

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06436144 2024-05-30

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06380348 2024-04-23

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06323148 2024-03-21

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Phase 3 Not yet recruiting

Lung Neoplasms, Neoplasm, Residual

NCT06319950 2024-03-20

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Phase 2 Not yet recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06142617 2023-11-21

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06067776 2023-10-05

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06018688 2023-09-21

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung